Literature DB >> 25708126

Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life.

R Baz1, H M Lin, A-M Hui, R D Harvey, K Colson, K Gallop, P Swinburn, J Laubach, D Berg, P Richardson.   

Abstract

PURPOSE: Little qualitative research exploring the impact of multiple myeloma (MM) and its treatment on the health-related quality of life (HRQL) of patients has been published. This study aimed to explore the burden of MM symptoms and treatment and the impact of these on HRQL. A model was developed to illustrate key concepts and their interrelationships.
METHODS: Patients with MM were recruited to this cross-sectional, qualitative study through a patient panel and at two clinical sites in the USA. An interview discussion guide was developed using a review of published literature and interviews with experienced MM clinicians. In-depth, semistructured telephone interviews with MM patients were conducted to explore their experiences of the disease and its treatment. Data were analyzed using a thematic analysis approach.
RESULTS: Twenty MM patients at various stages of treatment participated in open-ended, semistructured interviews. Patients reported both current and previous MM symptoms; most had experienced fatigue and pain. Other commonly reported symptoms were fractures, anemia, neuropathy, aches, and infections. MM treatment was found to have a negative impact on patients' HRQL; treatment-related adverse events included fatigue, neuropathy, insomnia, and gastrointestinal symptoms. MM treatment placed a substantial psychological and physical burden on patients, disrupting social activities, decreasing independence, and impacting on relationships. A model was developed to illustrate the relationship between these concepts.
CONCLUSION: The conceptual model developed in this study illustrates the many aspects of MM and its treatment and how they can have a negative impact on patients' HRQL.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25708126     DOI: 10.1007/s00520-015-2644-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  19 in total

Review 1.  Management of acute hypercalcemia.

Authors:  J P Bilezikian
Journal:  N Engl J Med       Date:  1992-04-30       Impact factor: 91.245

Review 2.  Multiple myeloma.

Authors:  Dean Smith; Kwee Yong
Journal:  BMJ       Date:  2013-06-26

Review 3.  Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.

Authors:  Paul G Richardson; Jacob Laubach; Constantine S Mitsiades; Robert Schlossman; Teru Hideshima; Katherine Redman; Dharminder Chauhan; Irene M Ghobrial; Nikhil Munshi; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2011-07-07       Impact factor: 6.998

4.  Living with multiple myeloma: experiences of patients and their informal caregivers.

Authors:  Alex Molassiotis; Barbara Wilson; Susan Blair; Tracy Howe; James Cavet
Journal:  Support Care Cancer       Date:  2009-12-09       Impact factor: 3.603

5.  Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners.

Authors:  Alex Molassiotis; Barbara Wilson; Susan Blair; Tracy Howe; James Cavet
Journal:  Psychooncology       Date:  2011-01       Impact factor: 3.894

6.  Patient-reported outcomes: conceptual issues.

Authors:  Margaret L Rothman; Philippe Beltran; Joseph C Cappelleri; Joseph Lipscomb; Bonnie Teschendorf
Journal:  Value Health       Date:  2007 Nov-Dec       Impact factor: 5.725

7.  The relationships among physiologic variables, quality of life, and fatigue in patients with multiple myeloma.

Authors:  Reanne Booker; Karin Olson; Linda M Pilarski; Joseph P Noon; Nizar J Bahlis
Journal:  Oncol Nurs Forum       Date:  2009-03       Impact factor: 2.172

Review 8.  Mechanisms of bone lesions in multiple myeloma and lymphoma.

Authors:  G D Roodman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 9.  Novel therapies in the treatment of multiple myeloma.

Authors:  Jacob P Laubach; Constantine S Mitsiades; Anuj Mahindra; Robert L Schlossman; Teru Hideshima; Dharminder Chauhan; Nicole A Carreau; Irene M Ghobrial; Noopur Raje; Nikhil C Munshi; Kenneth C Anderson; Paul G Richardson
Journal:  J Natl Compr Canc Netw       Date:  2009-10       Impact factor: 11.908

10.  Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation.

Authors:  Allen C Sherman; Stephanie Simonton; Umaira Latif; Thomas G Plante; Elias J Anaissie
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

View more
  18 in total

1.  'It is a journey of discovery': living with myeloma.

Authors:  Rosslyn de Wet; Heather Lane; Anil Tandon; Bradley Augustson; David Joske
Journal:  Support Care Cancer       Date:  2018-10-27       Impact factor: 3.603

2.  Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.

Authors:  Shaji Kumar; Philippe Moreau; Parameswaran Hari; Maria-Victoria Mateos; Heinz Ludwig; Chaim Shustik; Tamas Masszi; Andrew Spencer; Roman Hájek; Kenneth Romeril; Irit Avivi; Anna M Liberati; Monique C Minnema; Hermann Einsele; Sagar Lonial; Deborah Berg; Jianchang Lin; Neeraj Gupta; Dixie-Lee Esseltine; Paul G Richardson
Journal:  Br J Haematol       Date:  2017-05-09       Impact factor: 6.998

3.  Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development.

Authors:  Zhaoyang Teng; Neeraj Gupta; Zhaowei Hua; Guohui Liu; Vivek Samnotra; Karthik Venkatakrishnan; Richard Labotka
Journal:  Clin Transl Sci       Date:  2017-11-23       Impact factor: 4.689

Review 4.  Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Authors:  Paul G Richardson; Jesus F San Miguel; Philippe Moreau; Roman Hajek; Meletios A Dimopoulos; Jacob P Laubach; Antonio Palumbo; Katarina Luptakova; Dorothy Romanus; Tomas Skacel; Shaji K Kumar; Kenneth C Anderson
Journal:  Blood Cancer J       Date:  2018-11-09       Impact factor: 11.037

5.  Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.

Authors:  Mary Slavcev; Allison Spinelli; Elisabeth Absalon; Tara Masterson; Christoph Heuck; Annette Lam; Erwin De Cock
Journal:  Clinicoecon Outcomes Res       Date:  2021-06-08

6.  Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial.

Authors:  Stefan Knop; Maria-Victoria Mateos; Meletios A Dimopoulos; Kenshi Suzuki; Andrzej Jakubowiak; Chantal Doyen; Paulo Lucio; Zsolt Nagy; Ganna Usenko; Ludek Pour; Mark Cook; Sebastian Grosicki; Andre Crepaldi; Anna Marina Liberati; Philip Campbell; Tatiana Shelekhova; Sung-Soo Yoon; Genadi Losava; Tomoaki Fujisaki; Mamta Garg; Jianping Wang; Susan Wroblewski; Anupa Kudva; Katharine S Gries; John Fastenau; Jesus San-Miguel; Michele Cavo
Journal:  BMC Cancer       Date:  2021-06-02       Impact factor: 4.430

7.  The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials.

Authors:  Don Robinson; Dixie-Lee Esseltine; Antoine Regnault; Juliette Meunier; Kevin Liu; Helgi van de Velde
Journal:  Br J Haematol       Date:  2016-06-05       Impact factor: 6.998

Review 8.  New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib.

Authors:  Paul G Richardson; Shaji Kumar; Jacob P Laubach; Claudia Paba-Prada; Neeraj Gupta; Deborah Berg; Helgi van de Velde; Philippe Moreau
Journal:  J Blood Med       Date:  2017-08-22

9.  Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Craig C Hofmeister; Cara A Rosenbaum; Myo Htut; David H Vesole; Jesus G Berdeja; Michaela Liedtke; Ajai Chari; Stephen D Smith; Daniel Lebovic; Noopur Raje; Catriona Byrne; Eileen Liao; Neeraj Gupta; Alessandra Di Bacco; Jose Estevam; Deborah Berg; Rachid Baz
Journal:  Br J Haematol       Date:  2018-06-25       Impact factor: 6.998

10.  Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.

Authors:  Sudhir Manda; Habte A Yimer; Stephen J Noga; Saulius Girnius; Christopher A Yasenchak; Veena Charu; Roger Lyons; Jack Aiello; Kimberly Bogard; Renda H Ferrari; Dasha Cherepanov; Brittany Demers; Vickie Lu; Presley Whidden; Suman Kambhampati; Ruemu E Birhiray; Haresh S Jhangiani; Ralph Boccia; Robert M Rifkin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.